HUTCHMED launches global early-stage trial for novel ATTC cancer therapy HMPL-A580

HUTCHMED (China) ( (HK:0013) ) just unveiled an announcement.

HUTCHMED has begun a Phase I/IIa global clinical trial of HMPL-A580, its second novel Antibody-Targeted Therapy Conjugate, in patients with unresectable, advanced or metastatic solid tumors in China and the US. The first-in-class candidate couples a selective PI3K/PIKK inhibitor payload to an anti-EGFR antibody, aiming to exploit synergy between PAM pathway inhibition and EGFR blockade.

The multicenter, open-label study will assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy, first through dose escalation and then through expansion in selected solid tumors to define dosing for later-stage trials. The launch underscores HUTCHMED’s push to build a differentiated ATTC platform that seeks to improve tumor targeting, reduce off-tumor toxicity and position the company for future partnerships and earlier-line oncology treatment combinations.

More about HUTCHMED (China)

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It advances drug candidates from in-house discovery to global markets, with three medicines already marketed in China and one also approved in the US, Europe and Japan.

For detailed information about 0013 stock, go to TipRanks’ Stock Analysis page.